20 September 2018  
EMA/CHMP/616909/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Cabometyx 
cabozantinib 
On 20 September 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Cabometyx. The marketing authorisation holder for this medicinal product is Ipsen Pharma. 
The CHMP adopted a new indication as follows: 
“Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in 
adults who have previously been treated with sorafenib.” 
For information, the full indications for Cabometyx will be as follows:2 
“Renal Cell Carcinoma (RCC) 
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC): 
- in treatment-naïve adults with intermediate or poor risk (see section 5.1) 
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy 
Hepatocellular Carcinoma (HCC) 
CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma 
(HCC) in adults who have previously been treated with sorafenib.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
